Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019410 | 0.89 | HTR3E (0.53) | ADRA2AADRA2BADRA2CMAPTMAPK1 | |
| SCHEMBL29540837 | 0.81 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CMAPTMAPK1 | |
| SCHEMBL592019 | 0.81 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CMAPTMAPK1 | |
| SCHEMBL18876507 | 0.81 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CMAPTMAPK1 | |
| SCHEMBL27382765 | 0.80 | PNMT (0.47) | ADRA2AADRA2BADRA2CMAPTRAB9A | |
| SCHEMBL18879785 | 0.79 | HTT (0.39) | ADRA2AADRA2BADRA2CMAPTMAPK1 | |
| SCHEMBL21124236 | 0.77 | MAPT (0.49) | ADRA2AADRA2BADRA2CMAPTMAPK1 | |
| SCHEMBL13840331 | 0.76 | MAPT (0.58) | ADRA2AADRA2BADRA2CMAPTMAPK1 | |
| SCHEMBL11000954 | 0.75 | PNMT (0.34) | ADRA2AADRA2BADRA2CMAPTALDH1A1 | |
| SCHEMBL17705746 | 0.74 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024187093-A1 | ERK INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3296309-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit Gent (BE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2877480-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-9321796-B2 | Galactopyranosyl derivatives useful as medicaments | UNIVERSITEIT GENT (BE) | 2016-04-26 | — | — | US | disclosed |
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | AMBICION CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2877480-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit van Gent (BE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014001204-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIVERSITEIT GENT (BE) | 2014-01-03 | — | — | WO | disclosed |
| US-8227498-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 2-cyano(4-ethylphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine | PROBIODRUG AG (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| WO-1993010742-A2 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1993-06-10 | — | — | WO | disclosed |
| EP-0544765-A1 | PIPERAZINYL DERIVATIVES. | NOVO NORDISK AS (DK) | 1993-06-09 | — | — | EP | disclosed |
| US-5214053-A | THIOUREA DERIVATIVES AND ANTIMICROBIAL AGENT AND ANTIULCER AGENT CONTAINING THE SAME | TERUMO KABUSHIKI KAISHA (JP) | 1993-05-25 | — | — | US | disclosed |
| EP-0531228-A1 | Thiourea derivatives, antimicrobial agent and antiulcer agent containing the same | TERUMO KABUSHIKI KAISHA (JP) | 1993-03-10 | — | — | EP | disclosed |
| WO-1992003426-A1 | PIPERAZINYL DERIVATIVES | NOVO NORDISK A/S (DK) | 1992-03-05 | — | — | WO | disclosed |
| EP-0199400-B1 | Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-09-26 | — | — | EP | disclosed |
| US-4826848-A | Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-02 | — | — | US | disclosed |
| US-4749702-A | PARKINSON*S DISEASE, ENTEROKINESIA | JANSSEN PHARMACEUTICA N. V. (BE) | 1988-06-07 | — | — | US | disclosed |
| US-4689330-A | PARKINSON DISEASE | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-08-25 | — | — | US | disclosed |
| EP-0199400-A2 | Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210728-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | B3GAT3, GALR3, ST6GAL1 | ADRA2A 2262/4885ADRA2B 1138/4885ADRA2C 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.